Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 3/2011

Open Access 01-06-2011

Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy

Authors: Whitney B. Pope, Jonathan R. Young, Benjamin M. Ellingson

Published in: Current Neurology and Neuroscience Reports | Issue 3/2011

Login to get access

Abstract

Bevacizumab is thought to normalize tumor vasculature and restore the blood–brain barrier, decreasing enhancement and peritumoral edema. Conventional measurements of tumor response rely upon dimensions of enhancing tumor. After bevacizumab treatment, glioblastomas are more prone to progress as nonenhancing tumor. The RANO (Response Assessment in Neuro-Oncology) criteria for glioma response use fluid-attenuated inversion recovery (FLAIR)/T2 hyperintensity as a surrogate for nonenhancing tumor; however, nonenhancing tumor can be difficult to differentiate from other causes of FLAIR/T2 hyperintensity (eg, radiation-induced gliosis). Due to these difficulties, recent efforts have been directed toward identifying new biomarkers that either predict treatment response or accurately measure response of both enhancing and nonenhancing tumor shortly after treatment initiation. This will allow for earlier treatment decisions, saving patients from the adverse effects of ineffective therapies while allowing them to try alternative therapies sooner. An active area of research is the use of physiologic imaging, which can potentially detect treatment effects before changes in tumor size are evident.
Literature
1.
Norden AD, Drappatz J, Wen PY: Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. Dec 2008;7(12):1152–1160.PubMedCrossRef
2.
Wen PY, Macdonald DR, Reardon DA, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. Apr 10 2010;28(11):1963–1972.PubMedCrossRef
3.
Rees JH, Smirniotopoulos JG, Jones RV, Wong K: Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics. Nov 1996;16(6):1413–1438; quiz 1462–1413.PubMed
4.
Clarke JL, Chang S: Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. May 2009;9(3):241–246.PubMedCrossRef
5.
Brandsma D, van den Bent MJ: Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. December 2009;22(6):633–638.PubMedCrossRef
6.
Kim JH, Chung YG, Kim CY, et al.: Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci. Dec 2004;19(6):879–886.PubMedCrossRef
7.
Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. Feb 1 2007;67(2):323–326.PubMedCrossRef
8.
Hirai T, Murakami R, Nakamura H, et al.: Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol. Sep 2008;29(8):1505–1510.PubMedCrossRef
9.
Sawlani RN, Raizer J, Horowitz SW, et al.: Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging—pilot study. Radiology. May 2010;255(2):622–628.PubMedCrossRef
10.
Sorensen AG, Batchelor TT, Zhang WT, et al.: A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. Jul 1 2009;69(13):5296–5300.PubMedCrossRef
11.
Kamoun WS, Ley CD, Farrar CT, et al.: Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. May 20 2009;27(15):2542–2552.PubMedCrossRef
12.
Cha S, Knopp EA, Johnson G, et al.: Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol. May 2000;21(5):881–890.PubMed
13.
Akella NS, Twieg DB, Mikkelsen T, et al.: Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging. Dec 2004;20(6):913–922.PubMedCrossRef
14.
Mangla R, Singh G, Ziegelitz D, et al.: Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. Aug 2010;256(2):575–584.PubMedCrossRef
15.
•• Law M, Young RJ, Babb JS, et al.: Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. May 2008;247(2):490–498. This large, well-designed study demonstrated that rCBV can predict time to progression in both high-grade and low-grade gliomas. PubMedCrossRef
16.
Caseiras GB, Ciccarelli O, Altmann DR, et al.: Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology. Nov 2009;253(2):505–512.CrossRef
17.
Cao Y, Tsien CI, Nagesh V, et al.: Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys. Mar 1 2006;64(3):876–885.PubMedCrossRef
18.
•• Barajas RF, Jr., Chang JS, Segal MR, et al.: Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. Nov 2009;253(2):486–496. This well-conducted study demonstrated that DSC parameters (rCBV, relative peak height, and PSR) may help differentiate recurrent glioblastoma from radiation necrosis. PubMedCrossRef
19.
Hu LS, Baxter LC, Smith KA, et al.: Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. Mar 2009;30(3):552–558.PubMedCrossRef
20.
Sugahara T, Korogi Y, Tomiguchi S, et al.: Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. May 2000;21(5):901–909.PubMed
21.
Lev MH, Ozsunar Y, Henson JW, et al.: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. Feb 2004;25(2):214–221.PubMed
22.
Paulson ES, Schmainda KM: Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. Nov 2008;249(2):601–613.PubMedCrossRef
23.
Gahramanov S, Raslan AM, Muldoon LL, et al.: Potential for Differentiation of Pseudoprogression from True Tumor Progression with Dynamic Susceptibility-weighted Contrast-enhanced Magnetic Resonance Imaging using Ferumoxytol vs. Gadoteridol: A Pilot Study. Int J Radiat Oncol Biol Phys. Apr 13 2010.
24.
Moffat BA, Chenevert TL, Meyer CR, et al.: The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia. 2006;8(4):259–267.PubMedCrossRef
25.
Hamstra DA, Chenevert TL, Moffat BA, et al.: Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Nat Acad Sci. 2005;102(46):16759–16764.PubMedCrossRef
26.
Hamstra DA, Galbán CJ, Meyer CR, et al.: Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26(10):3387–3394.PubMedCrossRef
27.
Ellingson BM, Malkin MG, Rand SD, et al.: Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538–548.PubMedCrossRef
28.
Ellingson BM, Malkin MG, Rand SD, et al.: Functional diffusion maps applied to FLAIR abnormal areas are valuable for the clinical monitoring of recurrent brain tumors. Proc Intl Soc Mag Reson Med. 2009;17:285.
29.
Ellingson BM, Rand SD, Malkin MG, Schmainda KM: Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol. 2010;97(3):419–423.PubMedCrossRef
30.
Ellingson BM, Malkin MG, Rand SD, et al.: Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions. Proc Intl Soc Mag Reson Med. 2009;17:1010.
31.
Ellingson BM, Malkin MG, Rand SD, et al.: Volumetric analysis of functional diffusion maps (fDMs) is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant glioma. J Neurooncol. 2010;In Press.
32.
Rieger J, Bahr O, Muller K, et al.: Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol. Aug 2010;99(1):49–56.PubMedCrossRef
33.
Rieger J, Bahr O, Ronellenfitsch MW, et al.: Bevacizumab-Induced Diffusion Restriction in Patients With Glioma: Tumor Progression or Surrogate Marker of Hypoxia? J Clin Oncol. Jun 28 2010.
34.
Gerstner ER, Frosch MP, Batchelor TT: Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. Feb 20 2010;28(6):e91–93.PubMedCrossRef
35.
Gerstner ER, Chen PJ, Wen PY, et al.: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. May 2010;12(5):466–472.PubMed
36.
•• Pope WB, Kim HJ, Huo J, et al.: Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. Jul 2009;252(1):182–189. This well-conducted study demonstrated that ADC histogram analysis is 72.5% accurate in predicting 6-month progression-free survival in patients with glioblastoma treated with bevacizumab. PubMedCrossRef
37.
Smith EA, Carlos RC, Junck LR, et al.: Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol. Feb 2009;192(2):W45–52.PubMedCrossRef
38.
Weybright P, Sundgren PC, Maly P, et al.: Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol. Dec 2005;185(6):1471–1476.PubMedCrossRef
39.
Hattingen E, Delic O, Franz K, et al.: (1)H MRSI and progression-free survival in patients with WHO grades II and III gliomas. Neurol Res. Jul 2010;32(6):593–602.PubMedCrossRef
40.
Hattingen E, Raab P, Franz K, et al.: Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology. Sep 2008;50(9):759–767.PubMedCrossRef
41.
Oh J, Henry RG, Pirzkall A, et al.: Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. May 2004;19(5):546–554.PubMedCrossRef
42.
Chen W, Cloughesy T, Kamdar N, et al.: Imaging proliferation in brain tumors with 18 F-FLT PET: comparison with 18 F-FDG. J Nucl Med. Jun 2005;46(6):945–952.PubMed
43.
Chen W, Delaloye S, Silverman DH, et al.: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18 F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. Oct 20 2007;25(30):4714–4721.PubMedCrossRef
44.
Potzi C, Becherer A, Marosi C, et al.: [11 C] methionine and [18 F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol. Sep 2007;84(3):305–314.PubMedCrossRef
45.
Galldiks N, Ullrich R, Schroeter M, et al.: Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. Jan 2010;37(1):84–92.PubMedCrossRef
46.
Becherer A, Karanikas G, Szabo M, et al.: Brain tumour imaging with PET: a comparison between [18 F]fluorodopa and [11 C]methionine. Eur J Nucl Med Mol Imaging. Nov 2003;30(11):1561–1567.PubMedCrossRef
47.
Chen W, Silverman DH, Delaloye S, et al.: 18 F-FDOPA PET imaging of brain tumors: comparison study with 18 F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. Jun 2006;47(6):904–911.PubMed
Metadata
Title
Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy
Authors
Whitney B. Pope
Jonathan R. Young
Benjamin M. Ellingson
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 3/2011
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-011-0179-x

Other articles of this Issue 3/2011

Current Neurology and Neuroscience Reports 3/2011 Go to the issue

ReviewPaper

NMDA Receptor Antibody Encephalitis

ReviewPaper

Recent Advances in the Genetics of Hereditary Axonal Sensory-Motor Neuropathies Type 2

ReviewPaper

Molecular Mechanisms of PINK1-Related Neurodegeneration

ReviewPaper

Genomic Profiles of Glioma

ReviewPaper

Adult Primary Intradural Spinal Cord Tumors: A Review

ReviewPaper

Current State of Our Knowledge on Brain Tumor Epidemiology